This site is intended for healthcare professionals outside the US

Dosing Sandostatin® LAR® for Acromegaly

Print |

Dosing1*

  • The recommended initial dosing of Sandostatin® LAR® is 20 mg administered at 4-week intervals for 3 months
  • Subsequent dosage adjustment should be based on
    • GH and IGF-1 concentrations
    • Clinical symptoms

For patients currently receiving s.c. Sandostatin® Injection

  • The initial dose of Sandostatin® LAR® can be given the day after the last dose of s.c. Sandostatin®

Managing Sandostatin® LAR® dosing over time1
Dosing over time

For patients uncontrolled on Sandostatin® LAR®

  • Patients whose GH and IGF-1 levels are not controlled within 3 months
    • Dose may be increased to 30 mg every 4 weeks
  • If after 3 months, GH, IGF-1, and/or symptoms are not adequately controlled at a dose of 30 mg
    • Dose may be increased to 40 mg every 4 weeks

For patients consistently controlled on Sandostatin® LAR®

  • Patients whose GH is consistently <1 µg/L and IGF-1 is normalized and in whom most reversible signs/symptoms of acromegaly have disappeared after 3 months of treatment with 20 mg
    • Dose may be decreased to 10 mg every 4 weeks
    • However, particularly in this group of patients, it is recommended to closely monitor adequate control of serum GH and IGF-1 concentrations, and clinical signs/symptoms at this low dose of Sandostatin® LAR®
  • For patients on a stable dose of Sandostatin® LAR®, assessment of GH and IGF-1 should be made every 6 months

*The dosing information on this page applies only to patients prescribed Sandostatin® LAR® for acromegaly.

 

Reference:
1. Sandostatin® LAR® Summary of Product Characteristics. Novartis Pharma AG. 2016.

Please see the Summary of Product Characteristics.